D
ADMA Biologics, Inc.
ADMA
$6.55
$0.111.71%
D
Sell
3/14/2023Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the total return index.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the total return index.
D
Sell
2/23/2023Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 2/8/2023 due to a large decline in the growth index, valuation index and solvency index. The quick ratio declined from 2.54 to 1.26, debt to equity increased from 1.23 to 1.42, and earnings per share declined from -$0.0701 to -$0.08.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 2/8/2023 due to a large decline in the growth index, valuation index and solvency index. The quick ratio declined from 2.54 to 1.26, debt to equity increased from 1.23 to 1.42, and earnings per share declined from -$0.0701 to -$0.08.
D
Sell
8/15/2022Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D from D+ on 8/15/2022 due to a decline in the valuation index and solvency index. The quick ratio declined from 3.01 to 2.54, and debt to equity increased from 1.1 to 1.23.
ADMA Biologics, Inc. (ADMA) was downgraded to D from D+ on 8/15/2022 due to a decline in the valuation index and solvency index. The quick ratio declined from 3.01 to 2.54, and debt to equity increased from 1.1 to 1.23.
D
Sell
7/11/2022Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D+ from D on 7/11/2022 due to an increase in the volatility index and total return index.
ADMA Biologics, Inc. (ADMA) was upgraded to D+ from D on 7/11/2022 due to an increase in the volatility index and total return index.
D
Sell
6/24/2022Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D from D+ on 6/24/2022 due to a decline in the volatility index.
ADMA Biologics, Inc. (ADMA) was downgraded to D from D+ on 6/24/2022 due to a decline in the volatility index.
D
Sell
6/8/2022Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D+ from D on 6/8/2022 due to an increase in the volatility index and total return index.
ADMA Biologics, Inc. (ADMA) was upgraded to D+ from D on 6/8/2022 due to an increase in the volatility index and total return index.
D
Sell
5/5/2022Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index, total return index and valuation index.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
4/20/2022Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
11/15/2021Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 58.43% from -$32.26M to -$13.41M, total revenue increased 15.98% from $17.83M to $20.68M, and earnings per share increased from -$0.1484 to -$0.1324.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 58.43% from -$32.26M to -$13.41M, total revenue increased 15.98% from $17.83M to $20.68M, and earnings per share increased from -$0.1484 to -$0.1324.
D
Sell
11/8/2021Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index, growth index and volatility index.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index, growth index and volatility index.
D
Sell
5/1/2020Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index. Total revenue increased 66.66% from $7.22M to $12.04M, operating cash flow increased 16.84% from -$23.63M to -$19.65M, and EBIT increased 13.52% from -$9.05M to -$7.83M.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index. Total revenue increased 66.66% from $7.22M to $12.04M, operating cash flow increased 16.84% from -$23.63M to -$19.65M, and EBIT increased 13.52% from -$9.05M to -$7.83M.
D
Sell
1/25/2018Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 1/25/2018 due to an increase in the volatility index and total return index.
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 1/25/2018 due to an increase in the volatility index and total return index.
E
Sell
10/31/2017Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to E+ from D- on 10/31/2017 due to a decline in the volatility index.
ADMA Biologics, Inc. (ADMA) was downgraded to E+ from D- on 10/31/2017 due to a decline in the volatility index.
D
Sell
8/11/2017Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 8/11/2017 due to a decline in the efficiency index, total return index and volatility index. Net income declined 38.24% from -$6.54M to -$9.04M.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 8/11/2017 due to a decline in the efficiency index, total return index and volatility index. Net income declined 38.24% from -$6.54M to -$9.04M.
D
Sell
5/12/2017Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/12/2017 due to an increase in the efficiency index.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 5/12/2017 due to an increase in the efficiency index.
D
Sell
5/31/2016Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 5/31/2016 due to a significant increase in the solvency index, valuation index and total return index. Debt to equity declined from 17.42 to -4.28.
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 5/31/2016 due to a significant increase in the solvency index, valuation index and total return index. Debt to equity declined from 17.42 to -4.28.
E
Sell
3/24/2016Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to E+ from D- on 3/24/2016 due to a substantial decline in the solvency index, valuation index and total return index. Debt to equity increased from 2.88 to 17.42, and the quick ratio declined from 5.15 to 4.21.
ADMA Biologics, Inc. (ADMA) was downgraded to E+ from D- on 3/24/2016 due to a substantial decline in the solvency index, valuation index and total return index. Debt to equity increased from 2.88 to 17.42, and the quick ratio declined from 5.15 to 4.21.
D
Sell
3/11/2016Downgrade
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.48 to 2.88, and the quick ratio declined from 7.59 to 5.15.
ADMA Biologics, Inc. (ADMA) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.48 to 2.88, and the quick ratio declined from 7.59 to 5.15.
D
Sell
11/3/2014Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 11/3/2014 due to a substantial increase in the total return index, growth index and volatility index.
ADMA Biologics, Inc. (ADMA) was upgraded to D from D- on 11/3/2014 due to a substantial increase in the total return index, growth index and volatility index.
D
Sell
7/1/2014Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 7/1/2014 due to an increase in the volatility index, growth index and efficiency index. Total revenue increased 268.07% from $424 to $1.56M, operating cash flow increased 70.29% from -$2.96M to -$5.04M, and EBIT increased 25.8% from -$4.52M to -$5.68M.
ADMA Biologics, Inc. (ADMA) was upgraded to D- from E+ on 7/1/2014 due to an increase in the volatility index, growth index and efficiency index. Total revenue increased 268.07% from $424 to $1.56M, operating cash flow increased 70.29% from -$2.96M to -$5.04M, and EBIT increased 25.8% from -$4.52M to -$5.68M.
E
Sell
4/1/2014Upgraded
ADMA Biologics, Inc. (ADMA) was upgraded to E+ from E on 4/1/2014 due to an increase in the solvency index, volatility index and efficiency index. Total capital increased 536.68% from $4.19M to $26.65M, the quick ratio increased from 2.27 to 7.95, and debt to equity declined from -6.69 to 0.24.
ADMA Biologics, Inc. (ADMA) was upgraded to E+ from E on 4/1/2014 due to an increase in the solvency index, volatility index and efficiency index. Total capital increased 536.68% from $4.19M to $26.65M, the quick ratio increased from 2.27 to 7.95, and debt to equity declined from -6.69 to 0.24.
NASDAQ
04/26/2024 4:00PM Eastern
Quotes delayed
